CTNNB1 Families Advancing Research (CFAR) is a national, public, 501(c)(3), non-profit organization committed to funding scientific research and promoting the most promising scientific initiatives.
CFAR envisions a world where CTNNB1 Syndrome is fully understood and all individuals have access to life-changing treatments.
CFAR’s mission is to fund innovative research and advance public understanding of treatments by working directly with scientists, families, clinicians, government agencies, pharmaceutical companies, and partner organizations committed to curing CTNNB1 Syndrome
The milestones shown below mark the progress we’ve achieved together on the road to treatments and cures for CTNNB1 Syndrome.
In 2019, the Cochran and Dashiell families founded Advancing CTNNB1 Cures and Treatments (ACCT) after learning there were no therapies for CTNNB1 Syndrome beyond supportive care. Motivated by their children and driven by hope, they began raising funds and rallying the scientific community to take action
ACCT became a turning point—uniting families, researchers, and partners such as the Jacobs Lab at Tufts University to launch the first dedicated CTNNB1 research initiatives.
In 2020, ACCT joined forces with CTNNB1 Syndrome Awareness Worldwide to form CTNNB1 Connect & Cure (CCC), expanding the global network of families, scientists, and advocates committed to accelerating progress.
By 2025, select members of the CCC Board established CTNNB1 Families Advancing Research (CFAR), which is a first-of-its-kind Research Advocacy Organization (RAO) devoted exclusively to empowering CTNNB1 researchers, advancing discovery, and educating the public about scientific breakthroughs.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Consequat pede primis placerat senectus hac molestie et ultricies eros
888-7337-234
Send Now!
Monday – Saturday (10:30 AM – 7:00 PM)
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.